In another study, they targeted DCLK1 as a critical oncogenic regulatory factor using nanoparticle (NP) technology to deliver DCLK1-specific small interfering RNA (siRNA) in HCT116 xenografts aimed to upregulate tumor suppressor microRNAs (let-7a, miR-200a, and miR-144) for cancer therapy in CRC [51]. The gene discussed is DCLK1; the disease is neoplasm.